What we cover
GLP-1 era
Obesity, diabetes, cardiovascular and renal indications, and the supply and reimbursement bottlenecks that define real access.
Prevention vs. treatment
Where the evidence base is moving the line - statins, antihypertensives, lifestyle - and what payers actually cover.
Pipeline
Next-gen incretins, oral GLP-1, dual and triple agonists, and the mechanism diversification post-semaglutide.
Patient pathway
Who actually gets diagnosed, who gets treated, and where the gaps sit between guideline and practice.
Latest signals
See all →Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Snapshots
See all →Cardiac amyloidosis therapy reference (2026)
Reference snapshot of cardiac amyloidosis therapy across AL and ATTR types.
Lipid management therapy reference (2026)
Reference snapshot of lipid management therapy across foundational, add-on, and emerging tiers.
HFrEF therapy reference (2026)
Reference snapshot of HFrEF therapy across the four-pillar standard, additional approved options, and emerging mechanism classes.
Explained
See all →What is AL amyloidosis?
Plain-language primer on AL amyloidosis, why early diagnosis matters so much, and how modern therapy works.
PCSK9 inhibitors and modern lipid therapy explained
Plain-language primer on PCSK9 and the modern range of lipid-lowering options.
What is heart failure?
Plain-language primer on heart failure, why the modern therapy is built around four foundational classes, and what is changing.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.